Trials & Tribulations Biden’s diagnosis is unfortunate but—statistically—not surprisingOf the 384 men serving in Congress, 48 are likely to be diagnosed with prostate cancer in their lifetime May 23, 2025Vol.51 No.20By Peter Nelson
Trials & Tribulations Unlocking the future of precision medicine:The untapped power of RNA May 23, 2025Vol.51 No.20By Eric Lefkofsky and Norman E. "Ned" Sharpless
A new AI tool enables speedy use of ASCO guidelines, eliminating typical errors May 23, 2025Vol.51 No.20By Claire Marie Porter
PAMN becomes CMCA—the Cancer Marketing & Communications Association—as its size and scope expand May 23, 2025Vol.51 No.20By Jacquelyn Cobb
Sponsored Harnessing big data and AI to combat colorectal cancer May 23, 2025Vol.51 No.20By Enrique Velazquez Villarreal
FreeIn the Archives Highlights in neuroendocrine cancer survivorship, research, and prevention in the Cancer History Project May 23, 2025Vol.51 No.20
PodcastThe Directors The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient livesIn a time of uncertainty, “react to the knowns, not the fear” May 16, 2025Vol.51 No.19By Katie Goldberg
Capitol Hill Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFsTo avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges May 16, 2025Vol.51 No.19By Jacquelyn Cobb and Claire Marie Porter
Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reducedNCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.” May 16, 2025Vol.51 No.19By Jacquelyn Cobb
Guest Editorial An opportunity for Trump: Position U.S. cancer science to lead the world May 16, 2025Vol.51 No.19By Wafik S. El-Deiry
